Comparison of Siccoral® spray, Stomatovis ® gargle, and Strefen ® lozenges on postoperative sore throat

J Anesth. 2014 Aug;28(4):494-8. doi: 10.1007/s00540-013-1749-7. Epub 2013 Nov 21.

Abstract

Purpose: Postoperative sore throat (POST) is a frequent complication caused by mucosal trauma to the pharyngeal, laryngeal, and tracheal airway after endotracheal intubation. We compared the effectiveness of Siccoral, Strefen, and Stomatovis treatments in alleviating POST.

Methods: This prospective, randomized, single-blinded, controlled trial compares the incidence of POST with Strefen lozenges, Siccoral spray, or Stomatovis gargle. Three hundred and twenty American Society of Anesthesiologists class I-III patients undergoing elective genitourinary surgery under general orotracheal anesthesia were randomly allocated to four groups of 80 patients each. In the postoperative awakening unit and during related services, POST was evaluated by a blinded anesthesiologist at 0, 1, 6, and 24 h post extubation.

Results: The highest incidence of POST occured at 0 and 1 h post extubation in all groups (P = 0.002 × 10(-7), P = 0.004 × 10(-6), respectively). A significantly lower incidence of POST was observed in Strefen and Siccoral groups at 0 and 1 h compared to Control group (Strefen: P = 0.004 × 10(-2), P = 0.007 × 10(-4); Siccoral: P = 0.003 × 10(-8), P = 0.007 × 10(-5), respectively). A significantly lower incidence of POST was observed with Siccoral treatment at 0 h post extubation (P = 0.002 vs. Strefen treatment). Although POST incidence was not significantly different between the Stomatovis and Control groups, it was lower in the Stomatovis group at 0 and 1 h (P = 0.026 and 0.013, respectively). The incidence of POST was similar in all groups at 6 and 24 h post extubation (P = 0.141 and 0.426, respectively).

Conclusion: Siccoral and Strefen can be effective in relieving POST in the early hours after extubation.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acetylcysteine / therapeutic use*
  • Adolescent
  • Adult
  • Aerosols
  • Aged
  • Aged, 80 and over
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / therapeutic use
  • Female
  • Flurbiprofen / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Mouthwashes / therapeutic use*
  • Pharmaceutical Solutions
  • Pharyngitis / etiology
  • Pharyngitis / prevention & control*
  • Piperidines / administration & dosage
  • Piperidines / therapeutic use
  • Postoperative Complications / drug therapy*
  • Prospective Studies
  • Remifentanil
  • Tablets
  • Treatment Outcome
  • Young Adult

Substances

  • Aerosols
  • Analgesics, Opioid
  • Mouthwashes
  • Pharmaceutical Solutions
  • Piperidines
  • Tablets
  • Flurbiprofen
  • Remifentanil
  • Acetylcysteine

Associated data

  • ANZCTR/ACTRN12613000477729